entertainment -WSS

entertainment

author：fashion 2025-09-28 07:07:50 - browse：2

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why failed clinical trials don’t always spell doom for a new drug

WSS

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Pediatric cancer treatments threatened by a new FDA policy

Mayo Clinic plans $5B tech

Cigna, Humana reportedly in talks to merge

NIH trials fail to test meaningful long Covid therapies, experts say

focus

entertainment

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Why failed clinical trials don’t always spell doom for a new drug

Drug repurposing or repositioning? The language matters

Pediatric cancer treatments threatened by a new FDA policy

The cancer drug shortage isn’t new — and neither are the solutions

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Medicare proposal to cover medical devices draws a mixed reaction

BIO selects John Crowley as new CEO

Sports medicine is finally prioritizing gender equality

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

knowledge

Drastic changes should bring profitability, startup health insurers say

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Friends ask where James Watson's attitudes about race came from

Maui's cultural, historic landmarks damaged in the devastating wildfires

What to do when lifesaving products contribute to climate change

As biotech industry slumps, bioscience job market is upside down

hotspot

knowledge

explore

hotspot